Format

Send to

Choose Destination
See comment in PubMed Commons below
Nat Commun. 2015 Jun 17;6:7419. doi: 10.1038/ncomms8419.

Characterization of twenty-five ovarian tumour cell lines that phenocopy primary tumours.

Author information

  • 1Department of Pathology, Interdisciplinary Stem Cell Institute, Braman Family Breast Cancer Institute, and Sylvester Comprehensive Cancer Center, Miller School of Medicine, University of Miami, Miami, Florida 33136, USA.
  • 2Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, North Carolina 27514, USA.
  • 3Department of Pathology, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts 02115, USA.
  • 4Department of Systems Biology, MD Anderson Cancer Center, Houston, Texas 77030, USA.
  • 5Department of Cell Biology, Harvard Medical School, Boston, Massachusetts 02115, USA.
  • 6Department of Bioinformatics and Computational Biology, MD Anderson Cancer Center, Houston, Texas 77030, USA.
  • 7Department of Molecular and Cellular Pharmacology, University of Miami Miller School of Medicine, Miami, Florida 33136, USA.
  • 8Vincent Center for Reproductive Biology, Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts 02114, USA.

Abstract

Currently available human tumour cell line panels consist of a small number of lines in each lineage that generally fail to retain the phenotype of the original patient tumour. Here we develop a cell culture medium that enables us to routinely establish cell lines from diverse subtypes of human ovarian cancers with >95% efficiency. Importantly, the 25 new ovarian tumour cell lines described here retain the genomic landscape, histopathology and molecular features of the original tumours. Furthermore, the molecular profile and drug response of these cell lines correlate with distinct groups of primary tumours with different outcomes. Thus, tumour cell lines derived using this methodology represent a significantly improved platform to study human tumour pathophysiology and response to therapy.

PMID:
26080861
PMCID:
PMC4473807
DOI:
10.1038/ncomms8419
[PubMed - indexed for MEDLINE]
Free PMC Article
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Nature Publishing Group Icon for PubMed Central
    Loading ...
    Support Center